Ningde's business in Europe has made progress. Through cooperation with local European giants, it has invested 30 billion RMB, with each party holding 50% of the shares. This is a new mode of exploring the sea! It is worth noting that this cooperation with Stellantis is mainly to supply lithium iron batteries and drive a new round of electrification in Europe through Ferrous lithium phosphate parity technology, which is a new opportunity from 0 to 1.Ningde's business in Europe has made progress. Through cooperation with local European giants, it has invested 30 billion RMB, with each party holding 50% of the shares. This is a new mode of exploring the sea! It is worth noting that this cooperation with Stellantis is mainly to supply lithium iron batteries and drive a new round of electrification in Europe through Ferrous lithium phosphate parity technology, which is a new opportunity from 0 to 1.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.
Shanghai's action plan for mergers and acquisitions is still very strong! Three years to cultivate 10 head companies, forming a scale of 300 billion mergers and acquisitions, which clearly accelerate the merger of securities companies and build a first-class investment bank. This is a semiconductor leader, a pharmaceutical leader, a new material leader, a brokerage leader, etc., which directly benefits Shanghai local stocks and pays attention to Shanghai's advantages. This time, the merger with assets exceeding 2 trillion is clearly activated, which shows great determination.News:Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.
After the market closed, the Shanghai Municipal Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027). Among them, it is proposed to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials, forming a scale of M&A transactions of 300 billion yuan and activating total assets of over 2 trillion yuan. In addition, the plan also mentioned that the merger of securities companies should be accelerated to build a first-class investment bank.China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.True Vision: The controlling shareholder and others intend to reduce their holdings by 4% in total;
Strategy guide
Strategy guide
12-13
Strategy guide
12-13
Strategy guide
12-13